Seeking Alpha

Unilife rebounds as Jefferies defends shares

Shares of Unilife (UNIS -0.2%) have bounced off morning lows to trade essentially unchanged after a pair of bearish articles pressured the stock early on.

Jefferies is out in defense, saying that with "the list of announced deals with blue chip companies seeming to grow by the day, UNIS finally appears to be delivering on its promises."

Buy rating reiterated.

Price target hiked to $6 from $3.50.

From other sites
Comments (4)
  • atrickpay
    , contributor
    Comments (502) | Send Message
    jefferies prior p.t. was $5.00, not $3.50, per this:
    4 Dec 2013, 01:28 PM Reply Like
  • Restino
    , contributor
    Comments (52) | Send Message
    If you read closer you will see they went from $5 down to $3.50 prior. Now they are upping it to $6.


    I used to be a heavy shorter on this stock because they never got a contract signed. However, now they are signing the deals weekly because their time has come. It takes years to get testing completed and that years is up. That is why all the contracts are hitting now.


    2 New contracts is the last days and weeks. 2 others just before that. And there are upfront payments with each deal signed such as $5 million, $10 million and $15 to $20 million. Then they get payments along the way. After that they get royalties and percentage of sales, etc.


    This company can no longer be shorted. It is way too much risk and it is a rising super star imo.


    Today you saw how the desperate shorts came out and tried to take it down. They did for a few minutes and then they started to cover. It was a tick to exit their short position. Now that is done we are going up toward the price targets of $6.5 and $8.


    I am long, buying more each dip and holding everything until $8. I will then sell a quarter off and keep the rest for huge profit toward $10 and greater.
    4 Dec 2013, 05:44 PM Reply Like
  • atrickpay
    , contributor
    Comments (502) | Send Message
    oh i misread, thanks
    5 Dec 2013, 09:27 AM Reply Like
  • smallcap sleuth
    , contributor
    Comments (193) | Send Message
    I am new to the stock, bot just prior to the Novartis announcement. Lucky me and I bot in volume! The simple fact is that huge pharma is using these products NOT Bd s or Cs yeah it is a small deal in a long pipeline but it was chosen and is being used in the trials so if approved its married to the drug. This looks very real to this cynical investor who has been involved in some frisky questionable circumstances. I stay long and expect to see a flw of additional announcements involving big pharma, they are careful of who they get into bed with. Their eyes are wide open they know of the controversies but after checking the or ducts they voted YES. If it were BS and only hype they would not be doing these deals, and they do not want details of their agreements touted around. Normally controversies keep me away this one is an entry point.
    4 Dec 2013, 07:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs